News >

FDA Approves Bevacizumab as Frontline Ovarian Cancer Treatment After Surgery

Jason M. Broderick @jasoncology
Published: Wednesday, Jun 13, 2018

The FDA has approved bevacizumab (Avastin) for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.

Beyond ovarian cancer, bevacizumab also has approved indications in colorectal cancer, cervical cancer, lung cancer, renal cell carcinoma, and glioblastoma.  


  1. FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery. Genentech. Published June 13, 2018. Accessed June 13, 2018.
  2. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication